ArticleClinical case reports2025
Adalimumab as a Potential Therapeutic Option for Metastatic Crohn's Disease With Genital Lesions and Edema: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Recurrent vulvar abscess as the initial manifestation of Crohn's disease in an adolescent.Frontiers in medicine · 2026Article
- Adalimumab as a Potential Therapeutic Option for Metastatic Crohn's Disease With Genital Lesions and Edema: A Case Report.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastatic Crohn's disease (MCD) is a rare and complex extraintestinal manifestation of Crohn's disease (CD) that often profoundly affects patients' quality of life. This report presents a meticulously detailed case of a 12-year-old Iranian girl with persistent labial swelling and genital lesions, later diagnosed as MCD. The case highlights the diagnostic challenges and successful treatment with adalimumab. The study sheds light on the diagnostic intricacies, therapeutic dilemmas, and limited treatment options associated with MCD, a rare condition. This case study advances our understanding of MCD treatment and paves the way for exploring the promising efficacy of adalimumab in managing this challenging condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.